Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Amylyx Pharmaceuticals, Inc. (AMLX) vs Indivior Pharmaceuticals Inc. (INDV)

Amylyx Pharmaceuticals, Inc. and Indivior Pharmaceuticals Inc. are both Drug Manufacturers Specialty & Generic companies. Indivior Pharmaceuticals Inc. is the larger, with a market value of $4.3B against $3.8B — 1.1× the size. Amylyx Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Indivior Pharmaceuticals Inc. trades at 12.4×. Indivior Pharmaceuticals Inc. grew revenue faster over the last twelve months: 13.5% against −77.1%. Indivior Pharmaceuticals Inc. has the higher net margin (26.8% vs 0.00%) and the higher return on invested capital (460.5% vs 0.00%). Across the 16 metrics below, Indivior Pharmaceuticals Inc. leads on 13 and Amylyx Pharmaceuticals, Inc. on 3.

Valuation

Metric AMLX INDV Drug Manufacturers Specialty & Generic median
P/E n/m 12.40 20.14
P/S 37.53 3.20 2.25
P/B 13.71 n/m 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m 10.43 12.29
EV/Sales 34.68 3.42 2.56
Earnings yield (4.85%) 8.07% (2.99%)
Free cash flow yield (3.99%) (2.65%) 0.00%

Profitability

Metric AMLX INDV Drug Manufacturers Specialty & Generic median
Gross margin (42.65%) 81.97% 53.94%
Operating margin 0.00% 31.56% 0.00%
Net margin 0.00% 26.75% 0.00%
Free cash flow margin 0.00% (8.34%) 0.00%
Return on equity (74.73%) (153.12%) (0.40%)
Return on assets (66.25%) 26.52% (3.32%)
Return on invested capital 0.00% 460.53% 0.00%

Growth

Metric AMLX INDV Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (77.06%) 13.47% 10.01%
EPS growth (last fiscal year) 65.46% 3,017.87% —
Revenue growth, 5-year CAGR — 13.88% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AMLX INDV Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 (2.34) 0.05
Current ratio 12.12 0.84 2.31
Net debt to EBITDA 2.00 0.44 0.85

Dividend

Metric AMLX INDV Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 — 0.00

Size

Metric AMLX INDV Drug Manufacturers Specialty & Generic median
Market cap 3.78b 4.25b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack